Fusen Pharmaceutical Company Limited (FUSEN PHARM) reported no changes in its share capital structure for the month ended 31 July 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 3 August 2026.

Authorised and Issued Capital • Authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 20.00 million. • Issued shares stood at 739.30 million, identical to the previous month’s balance. The company held no treasury shares.

Public Float Compliance • FUSEN PHARM confirmed that it satisfied the Main Board’s minimum public-float requirement of 25% as of 31 July 2026.

Share Option Scheme Status • Under the Share Option Scheme adopted on 14 June 2018, a total of 16.00 million options remained outstanding at the end of July, with an exercise price of HKD 3.098 per share and an exercise window from 19 October 2019 to 13 June 2028. • No options were exercised during the month, leaving potential issuance capacity unchanged at 16.00 million shares and an aggregate 80.00 million shares available for grant under the scheme. • Consequently, no new shares were issued and no funds were raised from option exercises in July.

Overall, the company’s share capital structure, treasury share position, and authorised capital all remained stable during the reporting month. The filing also confirms full compliance with all applicable listing and regulatory requirements.